Duke Health Names Ophthalmology Chair

Why It Matters

Sadda’s expertise in AI‑driven retinal imaging positions Duke to accelerate precision eye care and attract high‑value research collaborations, strengthening its competitive edge in digital health.

Key Takeaways

• Dr. Sadda brings AI retinal imaging expertise to Duke Health
• Appointment strengthens Duke's research in advanced ophthalmic technologies
• Former ARVO president adds national leadership credibility
• Effective Nov. 10, Sadda will lead clinical and academic ophthalmology

Pulse Analysis

Duke Health announced that Dr. SriniVas Sadda will assume the chair of its Department of Ophthalmology on November 10. Sadda currently holds the A. Ray Irvine, Jr., MD Endowed Chair in Clinical Ophthalmology at the Doheny Eye Institute and serves as a professor at UCLA’s David Geffen School of Medicine. A Johns Hopkins‑trained neuro‑ophthalmologist, he has previously led the Doheny Eye Institute and the Association for Research in Vision and Ophthalmology, giving him a blend of academic, clinical, and organizational experience that aligns with Duke’s growth strategy.

Sadda’s research portfolio centers on automated retinal image analysis, substructure assessment, and next‑generation imaging platforms. These capabilities are at the core of the AI‑driven diagnostics wave reshaping ophthalmology, where early detection of diabetic retinopathy, age‑related macular degeneration, and glaucoma can be accelerated through machine‑learning algorithms. By integrating his expertise, Duke Health is positioned to expand its tele‑ophthalmology services, enhance clinical trial pipelines, and attract grant funding aimed at digital health innovation, reinforcing its reputation as a leader in precision eye care.

The appointment signals Duke’s commitment to marrying clinical excellence with cutting‑edge technology. As reimbursement models increasingly reward value‑based outcomes, the ability to deliver rapid, image‑based diagnoses can improve patient throughput and reduce costs. Moreover, Sadda’s national stature may draw collaborations with industry partners developing AI‑enabled devices, fostering revenue‑generating research contracts. For the broader market, the move underscores a trend where top‑tier academic institutions recruit leaders who can translate imaging breakthroughs into scalable, revenue‑positive health solutions.